Neumora Therapeutics (NMRA) Receivables - Other (2022 - 2024)

Neumora Therapeutics' Receivables - Other history runs 3 years deep, the most recent figure standing at $1.6 million for Q2 2024.

• In Q2 2024, Receivables - Other changed N/A year-over-year to $1.6 million; the TTM figure through Jun 2024 stood at $1.6 million (changed N/A YoY), while the FY2023 annual figure was $939000.0, up 2.18% from the prior year.
• Receivables - Other was $1.6 million for Q2 2024 at Neumora Therapeutics, up from $906000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.6 million in Q2 2024 to a low of $668000.0 in Q3 2023.
• Historically, Receivables - Other has averaged $1.0 million across 3 years, with a median of $919000.0 in 2022.
• Biggest YoY gain for Receivables - Other was 2.18% in 2023; the steepest drop was 2.18% in 2023.
• A 3-year view of Receivables - Other shows it stood at $919000.0 in 2022, then climbed by 2.18% to $939000.0 in 2023, then soared by 73.7% to $1.6 million in 2024.
• The last three Receivables - Other figures came in at $1.6 million (Q2 2024), $906000.0 (Q1 2024), and $939000.0 (Q4 2023), per Business Quant data.